Scott M. Lippman

Scott M. Lippman

Auto-generated profile, based on publicly available information

Scott M. Lippman

The University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
RHRoy S. Herbst
Roy S. Herbst
JHJohn V. Heymach
John V. Heymach
SLScott M. Lippman
Scott M. Lippman
The Molecular Origins of Cancer series continues with this review of molecular and genetic mechanisms of lung cancer. The authors review genetic susceptibility to lung cancer and four genes of importance in the evolution of the disease: EGFR, KRAS, the PI3K–Akt–mTOR complex, and TITF1. They also discuss gene profiling and protein profiling, with emphasis on the clinical value of these methods.

7 January 2009 in JAMA
Verified
Journal Article
Open access
PDF file
SLScott M. Lippman
Scott M. Lippman
EKEric Klein
Eric Klein
PGPhyllis J. Goodman
Phyllis J. Goodman
MLM. Scott Lucia
M. Scott Lucia
ITIan M. Thompson
Ian M. Thompson
CCCharles A. Coltman
Charles A. Coltman
Prostate cancer mortality in the United States has declined in recent years, but this cancer remains the most common nonskin epithelial malignancy in US men, with 186 320 new cases and 28 660 deaths (the second leading cause of cancer death) estimated for 2008.1 An effective prevention strategy for prostate cancer would have substantial public health benefits, including the potential to reduce the incidence of biologically indolent prostate cancer, which is significantly overdetected by widespread screening with prostate-specific antigen (PSA) and for which most newly diagnosed men still undergo curative-intent therapy involving substantial morbidity despite surgical and other advances.2-6

29 June 2010 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
FDFarshid Dayyani
Farshid Dayyani
CECarol J Etzel
Carol J Etzel
MLMei Liu
Mei Liu
CHChung-Han Ho
Chung-Han Ho
SLScott M Lippman
Scott M Lippman
ATAnne S Tsao
Anne S Tsao
HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC.

19 January 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SLScott M. Lippman
Scott M. Lippman
PGPhyllis J. Goodman
Phyllis J. Goodman
EKEric A. Klein
Eric A. Klein
HPHoward L. Parnes
Howard L. Parnes
ITIan M. Thompson
Ian M. Thompson
CCCharles A. Coltman
Charles A. Coltman
Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non–African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.

18 April 2001 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SLScott M. Lippman
Scott M. Lippman
JLJ. Jack Lee
J. Jack Lee
DKDaniel D. Karp
Daniel D. Karp
EVEverett E. Vokes
Everett E. Vokes
SBSteven E. Benner
Steven E. Benner
WHWaun Ki Hong
Waun Ki Hong
Background: Promising data have suggested that retinoid chemoprevention may help to control second primary tumors (SPTs), recurrence, and mortality of stage I non-small-cell lung cancer (NSCLC) patients. Methods: We carried out a National Cancer Institute (NCI) Intergroup phase III trial (NCI #I91–0001) with 1166 patients with pathologic stage I NSCLC (6 weeks to 3 years from definitive resection and no prior radiotherapy or chemotherapy). Patients were randomly assigned to receive a placebo or the retinoid isotretinoin (30 mg/day) for 3 years in a double-blind fashion. Patients were stratified at randomization by tumor stage, histology, and smoking status. The primary endpoint (time to SPT) and the secondary endpoints (times to recurrence and death) were analyzed by log-rank test and the Cox proportional hazards model. All statistical tests were two-sided. Results: After a median follow-up of 3.5 years, there were no statistically significant differences between the placebo and isotretinoin arms with respect to the time to SPTs, recurrences, or mortality. The unadjusted hazard ratio (HR) of isotretinoin versus placebo was 1.08 (95% confidence interval [CI] = 0.78 to 1.49) for SPTs, 0.99 (95% CI = 0.76 to 1.29) for recurrence, and 1.07 (95% CI = 0.84 to 1.35) for mortality. Multivariate analyses showed that the rate of SPTs was not affected by any stratification factor. Rate of recurrence was affected by tumor stage (HR for T2 versus T1 = 1.77 [95% CI = 1.35 to 2.31]) and a treatment-by-smoking interaction (HR for treatment-by-current-versus-never-smoking status = 3.11 [95% CI = 1.00 to 9.71]). Mortality was affected by tumor stage (HR for T2 versus T1 = 1.39 [95% CI = 1.10 to 1.77]), histology (HR for squamous versus nonsquamous = 1.31 [95% CI = 1.03 to 1.68]), and a treatment-by-smoking interaction (HR for treatment-by-current-versus-never-smoking = 4.39 [95% CI = 1.11 to 17.29]). Mucocutaneous toxicity (P<.001) and noncompliance (40% versus 25% at 3 years) were higher in the isotretinoin arm than in the placebo arm. Conclusions: Isotretinoin treatment did not improve the overall rates of SPTs, recurrences, or mortality in stage I NSCLC. Secondary multivariate and subset analyses suggested that isotretinoin was harmful in current smokers and beneficial in never smokers.

19 July 2000 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ISImad Shureiqi
Imad Shureiqi
DCDongning Chen
Dongning Chen
JLJ. Jack Lee
J. Jack Lee
PYPeiying Yang
Peiying Yang
RNRobert A. Newman
Robert A. Newman
SLScott M. Lippman
Scott M. Lippman
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to act via induction of apoptosis—programmed cell death—as potential colorectal cancer chemopreventive agents. NSAIDs can alter the production of different metabolites of polyunsaturated fatty acids (linoleic and arachidonic acids) through effects on lipoxygenases (LOXs) and cyclooxygenases. 15-LOX-1 is the main enzyme for metabolizing colonic linoleic acid to 13-S-hydroxyoctadecadienoic acid (13-S-HODE), which induces apoptosis. In human colorectal cancers, the expression of this enzyme is reduced. NSAIDs can increase 15-LOX enzymatic activity in normal leukocytes, but their effects on 15-LOX in neoplastic cells have been unknown. We tested the hypothesis that NSAIDs induce apoptosis in colorectal cancer cells by increasing the protein expression and enzymatic activity of 15-LOX-1. Methods: We assessed 15-LOX-1 protein expression and enzymatic activity, 13-S-HODE levels, and 15-LOX-1 inhibition in association with cellular growth inhibition and apoptosis induced by NSAIDs (primarily sulindac and NS-398) in two colorectal cancer cell lines (RKO and HT-29). All P values are two-sided. Results: Sulindac and NS-398 progressively increased 15-LOX-1 protein expression in RKO cells (at 24, 48, and 72 hours) in association with subsequent growth inhibition and apoptosis. Increased 13-S-HODE levels and the formation of 15-hydroxyeicosatetraenoic acid on incubation of the cells with the substrate arachidonic acid confirmed the enzymatic activity of 15-LOX-1. Inhibition of 15-LOX-1 in RKO cells by treatment with caffeic acid blocked NS-398-induced 13-S-HODE production, cellular growth inhibition, and apoptosis (P = .007, P<.0001, and P<.0001, respectively); growth inhibition and apoptosis were restored by adding exogenous 13-S-HODE (P<.0001 for each) but not its parent compound, linoleic acid (P = 1.0 for each). Similar results occurred with other NSAIDs and in HT-29 cells. Conclusions: These data identify 15-LOX-1 as a novel molecular target of NSAIDs for inducing apoptosis in colorectal carcinogenesis.